Cargando…
From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India
PURPOSE: To describe the increase in prevalence of ethambutol-induced optic neuropathy (EON) in patients presenting to a single tertiary referral eye care center in India after introduction of weight-based fixed dose combinations and an increase in duration of ethambutol use from 2016 in the Revised...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672794/ https://www.ncbi.nlm.nih.gov/pubmed/35918975 http://dx.doi.org/10.4103/ijo.IJO_3082_21 |
_version_ | 1784832819081510912 |
---|---|
author | Bhargava, Archana Sahoo, Niroj K Das, Anthony V Tyagi, Mudit Kammari, Priyanka Sheth, Jenil Kurada, Jayakrishna Shukla, Sneha |
author_facet | Bhargava, Archana Sahoo, Niroj K Das, Anthony V Tyagi, Mudit Kammari, Priyanka Sheth, Jenil Kurada, Jayakrishna Shukla, Sneha |
author_sort | Bhargava, Archana |
collection | PubMed |
description | PURPOSE: To describe the increase in prevalence of ethambutol-induced optic neuropathy (EON) in patients presenting to a single tertiary referral eye care center in India after introduction of weight-based fixed dose combinations and an increase in duration of ethambutol use from 2016 in the Revised National Tuberculosis Control Program. METHODS: This was a retrospective, observational, referral hospital-based study of 156 patients with a diagnosis of EON presenting to a single tertiary referral eye care center between January 2016 and December 2019. The main outcome measure was to assess the increase in prevalence of EON cases presenting to our tertiary care institute. RESULTS: During the 4-year study period, 156 new patients were diagnosed with EON. A total of 101 patients (64.7%) were males and 55 (35.3%) were females. The most common age group affected was 41–60 years. The significant complaint at presentation was decreased vision in all the patients. A rising trend in the number of patients diagnosed as EON was seen, with the prevalence increasing from 16 cases in 2016, 13 cases in 2017, and 31 cases in 2018 to 96 cases in 2019. CONCLUSION: The results of this study indicated an alarming increase in the trend of EON cases presenting to our tertiary care institute. |
format | Online Article Text |
id | pubmed-9672794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-96727942022-11-19 From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India Bhargava, Archana Sahoo, Niroj K Das, Anthony V Tyagi, Mudit Kammari, Priyanka Sheth, Jenil Kurada, Jayakrishna Shukla, Sneha Indian J Ophthalmol Special Focus, Neuroophthalmology, Original Article PURPOSE: To describe the increase in prevalence of ethambutol-induced optic neuropathy (EON) in patients presenting to a single tertiary referral eye care center in India after introduction of weight-based fixed dose combinations and an increase in duration of ethambutol use from 2016 in the Revised National Tuberculosis Control Program. METHODS: This was a retrospective, observational, referral hospital-based study of 156 patients with a diagnosis of EON presenting to a single tertiary referral eye care center between January 2016 and December 2019. The main outcome measure was to assess the increase in prevalence of EON cases presenting to our tertiary care institute. RESULTS: During the 4-year study period, 156 new patients were diagnosed with EON. A total of 101 patients (64.7%) were males and 55 (35.3%) were females. The most common age group affected was 41–60 years. The significant complaint at presentation was decreased vision in all the patients. A rising trend in the number of patients diagnosed as EON was seen, with the prevalence increasing from 16 cases in 2016, 13 cases in 2017, and 31 cases in 2018 to 96 cases in 2019. CONCLUSION: The results of this study indicated an alarming increase in the trend of EON cases presenting to our tertiary care institute. Wolters Kluwer - Medknow 2022-08 2022-07-29 /pmc/articles/PMC9672794/ /pubmed/35918975 http://dx.doi.org/10.4103/ijo.IJO_3082_21 Text en Copyright: © 2022 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Special Focus, Neuroophthalmology, Original Article Bhargava, Archana Sahoo, Niroj K Das, Anthony V Tyagi, Mudit Kammari, Priyanka Sheth, Jenil Kurada, Jayakrishna Shukla, Sneha From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India |
title | From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India |
title_full | From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India |
title_fullStr | From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India |
title_full_unstemmed | From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India |
title_short | From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India |
title_sort | from scylla to charybdis: fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in india |
topic | Special Focus, Neuroophthalmology, Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672794/ https://www.ncbi.nlm.nih.gov/pubmed/35918975 http://dx.doi.org/10.4103/ijo.IJO_3082_21 |
work_keys_str_mv | AT bhargavaarchana fromscyllatocharybdisfixeddrugcombinationsfortuberculosisandincreasedethambutolinducedopticneuropathyinindia AT sahoonirojk fromscyllatocharybdisfixeddrugcombinationsfortuberculosisandincreasedethambutolinducedopticneuropathyinindia AT dasanthonyv fromscyllatocharybdisfixeddrugcombinationsfortuberculosisandincreasedethambutolinducedopticneuropathyinindia AT tyagimudit fromscyllatocharybdisfixeddrugcombinationsfortuberculosisandincreasedethambutolinducedopticneuropathyinindia AT kammaripriyanka fromscyllatocharybdisfixeddrugcombinationsfortuberculosisandincreasedethambutolinducedopticneuropathyinindia AT shethjenil fromscyllatocharybdisfixeddrugcombinationsfortuberculosisandincreasedethambutolinducedopticneuropathyinindia AT kuradajayakrishna fromscyllatocharybdisfixeddrugcombinationsfortuberculosisandincreasedethambutolinducedopticneuropathyinindia AT shuklasneha fromscyllatocharybdisfixeddrugcombinationsfortuberculosisandincreasedethambutolinducedopticneuropathyinindia |